Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis.
Clinical Summary
In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis. A total of 2,760 patients were randomized to receive either apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily) or rivaroxaban (15 mg twice daily for 21 days followed by 20 mg daily) for 3 months.
The primary endpoint—clinically relevant bleeding (major or clinically relevant nonmajor bleeding)—occurred significantly less often with apixaban (3.3%) compared with rivaroxaban (7.1%), corresponding to a 54% relative risk reduction (RR 0.46; 95% CI 0.33–0.65; P<0.001). Mortality rates were low and similar between groups.
Clinical implication: Apixaban demonstrated a substantially lower bleeding risk than rivaroxaban while maintaining similar clinical outcomes, suggesting it may be the safer first-line direct oral anticoagulant for treatment of acute VTE in routine clinical practice.
This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The authors describe how distributed dopamine ensembles across...
Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now recognised as a key modulator of vascular...
The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025 meeting, several impactful studies were showcased, providing...
Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation starting from definitions, the need for pharmacological...
Copper dysregulation plays a central role in the pathogenesis of Wilson disease (WD). The disease arises from the body’s inability to regulate copper levels, leading to its accumulation and subsequent toxicity. Below is a detailed...
The molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease (ALD) involves complex interactions between the gut-liver-brain axis, immune system, neurotransmitters, and signaling pathways. Here is an in-depth explanation: ### **1. Alcohol Abstinence...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.